The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk
Abstract
Background: The apolipoprotein B (apoB)/apoA-I ratio represents the balance of proatherogenic and antiatherogenic lipoproteins. The purpose of this study was to determine whether the apoB/apoA-I ratio was superior to any of the cholesterol ratios – total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C), low-density lipoprotein cholesterol (LDL-C)/HDL-C and non-HDL-C/HDL-C – in predicting the risk of coronary disease. Moreover, we examined whether any lipids, lipoproteins or cholesterol ratios add significant predictive information beyond that provided by the apoB/apoA-I ratio. Methods: Plasma lipids, lipoproteins, apoB, and apoA-I were measured in 69,030 men and 57,168 women above 40years of age. After a mean follow-up of 98months, 1183 men and 560 women had died from a myocardial infarction in this prospective apolipoprotein-related mortality risk (AMORIS) study. Results: High apoB and a high apoB/apoA-I ratio were strongly related to increased coronary risk, while high apoA-I was inversely related to risk. The apoB/apoA-I ratio was superior to any of the cholesterol ratios in predicting risk. This advantage was most pronounced in subjects with LDL-C levels <3.6mmol/l. Addition of lipids, lipoproteins or any cholesterol ratio to apoB/apoA-I in risk models did not further improve the strong predictive value of apoB/apoA-I. Conclusions: These results indicate that the apoB/apoA-I ratio is at present the best single lipoprotein-related variable to quantitate coronary risk. Given the additional advantages apolipoproteins possess – fasting samples are not required, apoB/apoA-I is a better index of the adequacy of statin therapy than LDL-C, and the measurement of apoB and apoA-I are standardized, whereas LDL-C and HDL-C are not – there would appear to be considerable advantage to integrating apolipoproteins into clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290
De Backer, G. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00347-6 · Cited by 2,251
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Walldius, G., Jungner, I., Holme, I., Aastveit, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,229
Self-citationMetabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
Gotto, A. M., Whitney, E., Stein, E. A., Shapiro, D. R., Clearfield, M., Weis, S., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 563
De Backer, G., Ambrosioni, E., Borch-Johnsen, K., Brotons, C., Cifkova, R., Dallongeville, J., Ebrahim, S., Faergeman, O., Graham, I., Mancia, G., et al. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.02.013 · Cited by 508
Optimal low-density lipoprotein is 50 to 70 mg/dl
O'Keefe, J. H., Cordain, L., Harris, W. H., Moe, R. M., & Vogel, R. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.03.046 · Cited by 477
Lamarche, B., Moorjani, S., Lupien, P. J., Cantin, B., Bernard, P.-M., Dagenais, G. R., & Despre´s, J.-P. (1996) · Circulation · doi:10.1161/01.cir.94.3.273 · Cited by 476
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment
Sniderman, A., Furberg, C., Keech, A., van Lennep, J. R., Frohlich, J., Jungner, I., & Walldius, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12663-3 · Cited by 457
Self-citationWalldius, G., & Jungner, I. (2004) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01276.x · Cited by 396
Self-citationMarcovina, S. M., Albers, J. J., Henderson, L. O., & Hannon, W. H. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.5.773 · Cited by 342
Genest, J. J., Frohlich, J. J., Fodor, G. J., & McPherson, R. (2003) · PubMed · Cited by 342
Sniderman, A. D., Scantlebury, T., & Cianflone, K. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00014 · Cited by 336
Self-citationGrundy, S. M. (2002) · Circulation · doi:10.1161/01.cir.0000038419.53000.d6 · Cited by 309
Thrombogenic Factors and Recurrent Coronary Events
Moss, A. J., Goldstein, R. E., Marder, V. J., Sparks, C. E., Oakes, D., Greenberg, H., Weiss, H. J., Zareba, W., Brown, M. W., Liang, C.-S., et al. (1999) · Circulation · doi:10.1161/01.cir.99.19.2517 · Cited by 280
Measurement issues related to lipoprotein heterogeneity
Otvos, J. D., Jeyarajah, E. J., & Cromwell, W. C. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02632-2 · Cited by 260
Marcovina, S. M., Albers, J. J., Kennedy, H., Mei, J. V., Henderson, L. O., & Hannon, W. H. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.4.586 · Cited by 243
Talmud, P. J., Hawe, E., Miller, G. J., & Humphries, S. E. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000035521.22199.c7 · Cited by 233
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000133317.49796.0e · Cited by 195
Molecular mechanisms of reverse cholesterol transport
Barter, P. J., & Rye, K.-A. (1996) · Current Opinion in Lipidology · doi:10.1097/00041433-199604000-00006 · Cited by 181
Luc, G., Bard, J.-M., Ferrières, J., Evans, A., Amouyel, P., Arveiler, D., Fruchart, J.-C., & Ducimetière, P. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000022850.59845.e0 · Cited by 180
Jungner, I., Marcovina, S. M., Walldius, G., Holme, I., Kolar, W., & Steiner, E. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.8.1641 · Cited by 158
Self-citationBachorik, P. S., Lovejoy, K. L., Carroll, M. D., & Johnson, C. L. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.12.2364 · Cited by 155
The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations
Scharnagl, H., Nauck, M. A., Wieland, H., & März, W. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.068 · Cited by 141
Williams, K., Sniderman, A. D., Sattar, N. A., D’Agostino, R., Wagenknecht, L. E., & Haffner, S. M. (2003) · Circulation · doi:10.1161/01.cir.0000097113.11419.9e · Cited by 131
Self-citationPerformance of Four Homogeneous Direct Methods for LDL-Cholesterol
Miller, W. G., Waymack, P. P., Anderson, F. P., Ethridge, S. F., & Jayne, E. C. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.3.489 · Cited by 104
Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula
Sniderman, A. D., Blank, D., Zakarian, R., Bergeron, J., & Frohlich, J. (2003) · Clinical Biochemistry · doi:10.1016/s0009-9120(03)00117-6 · Cited by 100
Self-citationJungner, I., Walldius, G., Holme, I., Kolar, W., & Steiner, E. (1992) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02591655 · Cited by 80
Self-citationSniderman, A. D. (2004) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000137220.39031.3b · Cited by 69
Self-citationCoronary artery disease in patients at low risk — apolipoprotein AI as an independent risk factor
Francis, M. C., & Frohlich, J. J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00528-1 · Cited by 67
Usui, S., Kakuuchi, H., Okamoto, M., Mizukami, Y., & Okazaki, M. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.11.1946 · Cited by 42
Davidson, M. H. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.02.006 · Cited by 35
Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group
Graziani, M. S., Zanolla, L., Righetti, G., Marchetti, C., Mocarelli, P., & Marcovina, S. M. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.1.134 · Cited by 31
Collins-Nakai, R. L., & Dagenais, G. R. (1999) · PubMed · Cited by 18
Otvos, J. D. (2002) · Journal of Laboratory Medicine · doi:10.1515/labmed.2002.059 · Cited by 11
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
McQueen, M. J., Hawken, S., Wang, X., Ounpuu, S., Sniderman, A., Probstfield, J., Steyn, K., Sanderson, J. E., Hasani, M., Volkova, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61076-4 · Cited by 864
Self-citationLipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention
Munoz (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6269 · Cited by 760
WALLDIUS, G., & JUNGNER, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01643.x · Cited by 583
Self-citation
Metadata
- Authors
- Walldius, G., Jungner, I., Aastveit, A. H., Holme, I., Furberg, C. D., & Sniderman, A. D.
- Venue
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Publisher
- Walter de Gruyter GmbH
- Published
- 2004-01-01
- Volume
- 42
- Issue
- 12
- Pages
- 1355-63
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W2028440739
- Cited by
- 290
- References
- 39
- FWCI
- 17.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.